---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261612"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:55:20.940389+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics restructures, cuts 30% of workforce, pauses solid tumor trial, extends cash runway to H2 2027

## Summary
- FDA agrees to pivotal study design for TSC-101 in AML/MDS; trial to start Q2 2026.
- Workforce reduced by ~30% (66 roles); expects $2.3M severance charge in Q4 2025.
- Strategic prioritization yields ~$45M annual cost savings in 2026-27; cash runway extended to H2 2027.
- Pauses further enrollment in solid tumor Phase 1 PLEXI-T trial; to present initial data Q1 2026.
- First two patients dosed with multiplex TCR-T in solid tumors; shifting preclinical focus to in vivo engineering.

## SEC filing metadata
- accession: 0001193125-25-261612
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312525261612/0001193125-25-261612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312525261612/d873161d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261612
- JSON: https://secwatch.observer/filing/0001193125-25-261612.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261612.txt

## Source-grounded claims
- claim_id: 3f0a57bdb38e2128a3e60e09432e7594bded56f0
  claim: TScan Therapeutics, Inc. announced a restructuring with charges of up to approximately $2.3 million affecting the Company (approximately 30% of the Company’s workforce, or 66 roles).
  evidence_excerpt: On November 3, 2025, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the clinical development of its heme program, pause further enrollment in its solid tumor Phase 1 trial, and focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity. Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 30% of the Company’s workforce, or 66 roles. The Company expects to record a one-time charge of up to approximately $2.3 million during the three months ended December 31, 2025, for severance-related benefits and other costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312525261612/0001193125-25-261612-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.